Abstract
Background: The study analyses immunoexpression of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) based pathways which are mainstay of drug therapy in advanced and metastatic clear cell renal cell carcinoma (ccRCC) and to delineate their role as prognostic markers in a cohort of primary ccRCC. Methods: Descriptive study wherein immunohistochemical profiling of 100 cases of primary ccRCC was carried out using primary antibodies against mTOR, VEGF and CD34. Mean vascular density (MVD) and immunoreactivity was correlated with grading, staging, risk stratification and survival data. Results: mTOR and VEGF immunostaining was positive in 54% and 70% cases respectively with strong immunoreactivity correlating with high grade, high stage and high risk tumours with low survival. Inverse association was observed with MVD wherein low grade, low stage and low risk ccRCCs were associated with higher MVD. Conclusion: mTOR and VEGF expression in ccRCCs is associated with unfavourable prognosis. High MVD correlates with better outcome though concordance is limited by tumour heterogeneity.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Clinical and Diagnostic Pathology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
